Original language | English |
---|---|
Pages (from-to) | 1704-1705 |
Number of pages | 2 |
Journal | The Lancet |
Volume | 346 |
Issue number | 8991-8892 |
DOIs | |
State | Published - 30 Dec 1995 |
Externally published | Yes |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet, Vol. 346, No. 8991-8892, 30.12.1995, p. 1704-1705.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - False-memory syndrome
AU - Staples, Ian
AU - Sher, Leonid
N1 - Funding Information: SIR-A pH of 5 or less can protect against vaginal infections and sexually transmitted diseases, including AIDS.l,2 Lactobacilli can generate an acidic vaginal pH, and reduce the incidence of urogenital infections.3 We have shown that Lactobacillus casei subsp rhamnosus GR-1 could colonise the vagina.4 We now report that vaginal instillation of GR-1 and L fermentum B-54 in gelatin pessary (> 1 09 viable organisms) weekly for 1 year in ten premenopausal women (mean age 33; not using any spermicidal products) led to the maintenance of an acidic vaginal pH (mean 4-8 [SD 0-5] per patient during each month). The mean pH before the study was 5-0 (0-4). Urinary tract infections, however, still occurred, due to Escherchia coli (6), Streptococcus sp (3), Staphylococcus sp (3), and coliforms (1). The patients had a history of four or more recurrences of urinary tract infections (mean 6-3 per patient) in the previous year, and this dropped to 1-3 (79-4% drop) in the year of study. Lactobacilli GR-1 and B-54 were recovered each month from the vagina of each patient, and their colonisation was highest (mean 18.1 bacteria per vaginal cell, and 4 -1 x 101 viable organisms per mL vaginal sample) when the pH was 5-0. The patients reported no side-effects of treatment. A low pH per se, produced by lactobacillus colonisation of the vagina, does not appear to prevent all urogenital infections from occurring, although a lower rate of urinary tract infections with vaginal lactobacillus colonisation will be an important outcome for some patients. This work was supported by the Medical Research Council and Ontario Ministry of Health in Canada.
PY - 1995/12/30
Y1 - 1995/12/30
UR - http://www.scopus.com/inward/record.url?scp=0029609357&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(95)92868-5
DO - 10.1016/S0140-6736(95)92868-5
M3 - Letter
C2 - 8551841
AN - SCOPUS:0029609357
SN - 0140-6736
VL - 346
SP - 1704
EP - 1705
JO - The Lancet
JF - The Lancet
IS - 8991-8892
ER -